Methyl 7-Chloro-6,7,8-Trideoxy-6-(1-Methyl-Trans-4-Propyl-L-2-Pyrrolidinecarboxamido)-1-Thio-L-Threo-Alpha-D-Galacto-Octopyranoside 2-(Dihydrogen Phosphate)

Methyl 7-Chloro-6,7,8-Trideoxy-6-(1-Methyl-Trans-4-Propyl-L-2-Pyrrolidinecarboxamido)-1-Thio-L-Threo-Alpha-D-Galacto-Octopyranoside 2-(Dihydrogen Phosphate), assigned CAS registry number 24729-96-2 and conventionally designated clindamycin phosphate, constitutes the 2-(dihydrogen phosphate) ester of the semisynthetic lincosamide antibiotic clindamycin. The molecular formula C₁₈H₃₄ClN₂O₈PS corresponds to a relative molecular mass of 504.97 g/mol. Synthesized via selective phosphorylation of the parent octopyranoside 2‑OH group—typically employing phosphoryl chloride in the presence of a tertiary base followed by controlled hydrolysis—the compound is isolated as a white to off-white crystalline powder. A 10 g/L aqueous solution yields a pH of 3.5 to 4.5 at 25 °C. The substance is freely soluble in water (> 50 mg/mL), sparingly soluble in dehydrated ethanol, and practically insoluble in chloroform and diethyl ether. As a phosphate ester prodrug, it undergoes rapid in vivo enzymatic cleavage by alkaline phosphatases to liberate the microbiologically active free base, a feature exploited in parenteral and topical preparations where enhanced aqueous solubility and reduced injection-site irritation are prerequisite.

What Distinguishes This Phosphate Ester from Clindamycin Hydrochloride in Clinical Formulations?

Conversion of clindamycin to its phosphate ester alters three critical formulation parameters. A direct comparison between equimolar aqueous solutions of clindamycin phosphate and clindamycin hydrochloride reveals that the phosphate derivative exhibits a 10‑fold lower intrinsic pain score on intramuscular injection, as documented in early Phase I tolerability studies. This reduction is attributed to the phosphate ester’s lower osmolality at therapeutic concentrations and its buffering capacity near physiological pH after dilution. Solubility differs substantially: while clindamycin hydrochloride saturates at approximately 30 mg/mL in water, the phosphate ester routinely achieves concentrations exceeding 150 mg/mL, enabling high‑strength injectable formulations. Moreover, the rate of hydrolytic degradation in aqueous vehicles at pH 4.0–5.5 is approximately one‑third that of the hydrochloride salt, conferring a shelf‑life advantage for pre‑filled syringes and multi‑dose vials stored under refrigeration. Sterile bulk clindamycin phosphate intended for parenteral use is routinely dried to a residual moisture content ≤ 2.0% (w/w) to suppress solid‑state ester hydrolysis; exceeding this threshold during secondary drying of lyophilized cake can accelerate free clindamycin formation beyond the 1.0% specified individual impurity limit given in the United States Pharmacopeia monograph. In contrast to lincomycin, the 7‑chloro substitution and the trans‑4‑propyl‑L‑2‑pyrrolidinecarboxamido side chain confer a 4‑ to 8‑fold increase in in vitro potency against susceptible Gram‑positive cocci and anaerobic Gram‑negative rods. The phosphate ester retains this inherent activity profile while permitting formulation strategies unavailable to the free base. Free clindamycin base (CAS 18323-44-9) is practically insoluble in water and requires organic co‑solvents or surfactant systems for topical gel preparation, often resulting in crystalline precipitation during storage. The phosphate ester, by contrast, dissolves completely in the aqueous phase of hydroalcoholic acne lotions at 1.0% (w/w) without co‑solvent, maintaining a monophasic system that resists crystal nucleation over 24‑month stability windows when packaged in polyethylene terephthalate containers.

Pharmacopoeial Specifications and Analytical Verification

Batch release of clindamycin phosphate as an active pharmaceutical ingredient follows a compendial monograph framework, most commonly USP 43‑NF 38 or Ph. Eur. 10.3. The table below collates the primary quality attributes and corresponding acceptance criteria referenced in regulatory filings.

Attribute	Acceptance Criterion	Analytical Reference
Description	White or almost white, crystalline powder	Visual / Ph. Eur. 2.2.1
Identification A (IR)	Conforms to reference spectrum	Ph. Eur. 2.2.24
Identification B (HPLC)	Retention time matches standard	USP <621>
pH (10 g/L in CO₂‑free water)	3.5 – 4.5	Ph. Eur. 2.2.3
Water (Karl Fischer)	≤ 6.0% (w/w)	USP <921> Method Ia
Residue on Ignition	≤ 0.5%	USP <281>
Heavy Metals (as Pb)	≤ 20 ppm	Ph. Eur. 2.4.8 / ICH Q3D option 1
Related Substances – Clindamycin (total)	≤ 2.0%	USP <621> HPLC, C18 column, 210 nm
Related Substances – Any unspecified impurity	≤ 0.5%	USP <621> HPLC
Bacterial Endotoxins (parenteral grade)	< 0.35 EU/mg	USP <85> LAL kinetic chromogenic
Assay (anhydrous basis)	90.0% – 100.5% as C18H34ClN2O8PS	USP <621> HPLC

The chromatographic purity method employs a 4.6 × 150 mm octadecylsilane column, mobile phase consisting of phosphate buffer (pH 7.0) and acetonitrile in gradient mode, with UV detection at 210 nm. Resolution between clindamycin phosphate and the free base clindamycin must exceed 2.0 under these conditions. Failure of this system suitability criterion is commonly traced to column aging or insufficient phosphate buffer molarity; re‑equilibration with 50 mM buffer restores baseline separation.

When Lyophilized Cake Reconstitution Time Exceeds 60 Seconds

For vials labeled to contain 300–900 mg of clindamycin phosphate destined for intravenous infusion, the lyophilization cycle is designed to yield a coherent, porous cake that reconstitutes completely within 30 to 60 seconds upon addition of Water for Injection. A reconstitution time persistently above 60 seconds signals a deviation in the freezing or primary‑drying phase. Primary‑drying shelf temperature is typically maintained at −25 to −30 °C under a chamber pressure of 50–80 μbar. Should the shelf temperature inadvertently ascend above the collapse temperature (T_c) of the formulation—reported near −20 °C for a 5% (w/v) clindamycin phosphate solution—microcollapse of the ice‑vapor interface yields a densified cake structure with reduced surface area. This structure resists solvent penetration, prolonging reconstitution and generating particulate matter counts that may violate USP <788> limits for subvisible particles ≥ 10 μm. Post‑lyophilization annealing at 40 °C for 4 hours has been employed on production‑scale units to promote crystallization of the amorphous phosphate ester, lowering the specific surface area but improving storage stability; however, this step must be balanced against the risk of hydrolysis if vacuum integrity is lost. Process‑scale isolators equipped with tunable diode laser spectroscopy moisture sensors enable real‑time tracking of water desorption during secondary drying. Data from a 24‑square‑meter lyophilizer processing 50,000 vials per batch indicate that endpoint moisture readings plateau below 0.8% when shelf temperature ramps to 30 °C at 0.1 °C/min and held for 8 hours. Batches exhibiting residual moisture above 2.0% during stability storage at 40 °C/ 75% RH show an increase in the free clindamycin peak from 0.12% area to 1.4% area within 3 months, exceeding the compendial identification threshold.

Characterizing Degradation Products via HPLC-MS/MS

Forced degradation studies conducted under ICH Q1A(R2) conditions—hydrolytic stress at 0.1 M HCl, 0.1 M NaOH, and 3% H₂O₂, thermal stress at 105 °C dry air for 24 hours, and photolytic exposure per ICH Q1B Option 2—have catalogued the major degradants. The principal hydrolysis product is clindamycin free base, eluting at relative retention time 1.3 under the USP method. Oxidation yields the sulfoxide derivative detectable as a shoulder peak at RRT 0.85. High‑resolution mass spectrometry confirms the sulfoxide with a mass accuracy of Δ 1.2 ppm. Knowledge of these pathways guides excipient selection: preparations containing 0.1% edetate disodium exhibit a 40% reduction in oxidative degradation rate when stored in non‑nitrogen‑flushed containers. Formulators are advised to avoid amine‑functionalized buffer species above pH 6.0, as nucleophilic attack at the phosphorus center accelerates ester cleavage; tromethamine buffers, for instance, generate an N‑phosphorylated by‑product detectable by 31P NMR at δ 3.5 ppm. When manufacturing a topical gel containing 1.0% clindamycin phosphate, the compounding vehicle often includes a high‑molecular‑weight carbomer (e.g., Carbopol 981 or 980) neutralized with sodium hydroxide to a final pH of 5.0–5.5. Viscosity measurements performed on a Brookfield RVT viscometer with spindle #6 at 20 rpm consistently record values of 40,000–60,000 cP at 25 °C. Below pH 4.5, carbomer hydration is incomplete, resulting in low‑viscosity liquid formulations prone to phase separation; above pH 5.8, the phosphate ester hydrolysis rate accelerates measurably, with shelf‑life projections falling below the 24‑month target. The approved commercial gel formulation (as described in ANDA 062372) therefore incorporates a citrate‑phosphate buffer to hold pH within the narrow 4.8–5.4 window.

Property	Clindamycin Phosphate	Clindamycin Hydrochloride	Clindamycin Free Base
Aqueous solubility at 25 °C	> 150 mg/mL	~ 30 mg/mL	< 3 mg/mL
pH (10 g/L)	3.5–4.5	3.0–4.0	N/A (insoluble)
Primary route of administration	Parenteral (IM, IV), topical	Oral, occasional parenteral	Topical (with co‑solvent)
Injection‑site pain score (relative)	Low (1×)	Moderate–High ( 5 – 10×)	Not administered parenterally
Solution stability 25 °C/pH 4.5 (t90)	> 12 months	6–9 months	N/A
Melting point (decomposition)	~ 180–200 °C (dec.)	~ 143–148 °C	~ 83–86 °C

Differences in crystalline habit influence powder handling in solid‑dose manufacture. Clindamycin phosphate forms needle‑like crystals with an aspect ratio frequently exceeding 5:1, a morphology that complicates die‑filling operations on high‑speed encapsulation machinery. Roller‑compaction‑assisted granulation before encapsulation, maintaining a ribbon density of 1.10–1.20 g/cm³, has been deployed to improve flowability as measured by the Hausner ratio, bringing it below 1.25. In parallel, the hydrochloride monohydrate form exhibits a more equant crystal habit and may be directly encapsulated without granulation, although water activity constraints must be strictly monitored. The parenteral grade is isolated in a final crystallization step employing ethanol‑water mixtures. Control of the antisolvent addition rate—typically 0.5 L/min into a 50‑L crystallizer—determines the primary crystal size distribution. Median particle size (D₅₀) values of 25–40 µm are targeted to balance dissolution kinetics during lyophilization with filterability of the predried bulk solution through 0.2‑µm sterilizing‑grade filters. Particle sizes below 10 µm elevate the pressure differential across the filter cassette beyond 1.5 bar, triggering early filter change‑out and yield loss.

Processing Considerations for Aseptic Fill‑Finish of Phosphate Ester Solutions

The bulk drug solution for aseptic filling into pre‑sterilized glass vials is typically prepared at a concentration of 150 mg/mL (calculated as clindamycin) in Water for Injection. Temperature excursions above 40 °C during mixing must be avoided, as thermal stress promotes the formation of the N‑demethylated impurity, detectable at RRT 0.72 and controlled to ≤ 0.3% per the Ph. Eur. monograph. Aseptic processing under Grade A laminar‑flow conditions in an ISO 5 environment compliant with EU GMP Annex 1 requires that holding times of the sterile‑filtered bulk solution before filling do not exceed 24 hours at 2–8 °C. Bioburden monitoring of the pre‑filtration bulk using a validated membrane‑filtration method per Ph. Eur. 2.6.12 is expected to return counts below 10 CFU/ 100 mL. Any batch exhibiting a pre‑filtration bioburden above 50 CFU/ 100 mL necessitates re‑evaluation of the upstream purification column sanitization cycle, typically a 0.5 M sodium hydroxide flush of the ion‑exchange resin at 60 °C for 30 minutes. During final packaging, the stopper elastomer must be selected for low extractables and compatibility with the acidic phosphate ester. Chlorobutyl stoppers coated with a fluoropolymer film have been demonstrated to reduce leachable zinc dibutyldithiocarbamate levels to below the 0.5 ppb detection limit when tested according to the cone and plate extraction protocol of USP <381>. Uncoated bromobutyl stoppers rapidly acquire surface phosphate ester residues that catalyze barium‑induced glass delamination in Type I borosilicate vials after terminal sterilization at 121 °C for 15 minutes. This delamination, characterized by scanning electron microscopy revealing flake defects of 5–20 µm, has been traced back to a localized pH drop below 2.0 at the glass‑solution interface. Switching to an internally siliconized, non‑alkaline‑earth‑containing stopper formulation eliminates the phenomenon.